In addition to TCR-pMHCII, the enhanced HVEM-BTLA signaling and diminished TGFB-TGFBR and IL16-CD4 signalings between APCs and CD4+ T cells may represent other factors involved in the regulation of TCR downstream pathways in HD patients. This evidence concerns the gene CD4 and Huntington disease.